ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,187.67
0.00%
US Tech 100
17,589.60
-0.07%
Dow Jones
39,056.39
0.00%
Brent Oil
84.035
0.57%
Bitcoin
61,117.58
-0.11%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arvinas Inc (ARVN) Quote

Arvinas Inc

Arvinas Inc (ARVN)

NASDAQ
32.37
-1.96
(-5.71%)
Closed May 08 4:00PM
Delayed by 15 minutes
32.37
0.00
( 0.00% )
Pre Market: 7:00AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
32.37
Bid
32.14
Ask
35.35
Volume
81
0.00 Day's Range 0.00
13.57 52 Week Range 53.08
Market Cap
2.204B
Previous Close
32.37
Open
-
Last Trade
13
@
33.8
Last Trade Time
07:00:00
Financial Volume
-
VWAP
-
Average Volume (3m)
741,946
Shares Outstanding
68,083,928
Dividend Yield
-
PE Ratio
-6.00
Earnings Per Share (EPS)
-5.39
Revenue
78.5M
Net Profit
-367.3M

About Arvinas Inc

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arvinas.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arvinas Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARVN. The last closing price for Arvinas was $32.37. Over the last year, Arvinas shares have traded in a share price range of $ 13.57 to $ 53.08.

Arvinas currently has 68,083,928 shares outstanding. The market capitalization of Arvinas is $2.20 billion. Arvinas has a price to earnings ratio (PE ratio) of -6.00.

ARVN Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 07 2024
Edgar (US Regulatory)

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...

May 07 2024
GlobeNewswire Inc.

Arvinas to Present at Upcoming Investor Conferences

NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...

May 02 2024
GlobeNewswire Inc.

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

April 24 2024
GlobeNewswire Inc.

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...

April 11 2024
GlobeNewswire Inc.

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

March 18 2024
GlobeNewswire Inc.

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

March 04 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.75-2.2644927536233.1234.7731.6860928832.98275138CS
4-6.75-17.25460122739.1239.3430.9172777233.64202034CS
12-18.07-35.82474226850.4453.0830.9174194641.0567224CS
2615.5492.335115864516.8353.0814.024479816537.45605285CS
527.9932.772764561124.3853.0813.5761359932.25722579CS
156-31.25-49.119773656163.62108.46513.5750790147.27114443CS
26011.0651.900516189621.31108.46513.5749242446.91388916CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CPOPPop Culture Group Company Ltd
$ 2.90
(70.59%)
4.26M
SEZLSezzle Inc
$ 64.50
(44.17%)
28.19k
IVPInspire Veterinary Partners Inc
$ 5.16
(42.15%)
3.68M
ZLABZai Lab Ltd
$ 20.02
(20.82%)
67.64k
ZIMVZimVie Inc
$ 18.50
(20.29%)
879
EMKREMCORE Corporation
$ 1.785
(-38.45%)
69.12k
TIVCTivic Health Systems Inc
$ 0.86
(-35.82%)
542.05k
FWRDForward Air Corporation
$ 15.00
(-30.26%)
24.37k
CDLXCardlytics Inc
$ 10.30
(-29.45%)
37.9k
CTMXCytomX Therapeutics Inc
$ 3.10
(-26.01%)
2.55M
GWAVGreenwave Technology Solutions Inc
$ 0.0681
(17.21%)
16.18M
CPOPPop Culture Group Company Ltd
$ 2.90
(70.59%)
4.26M
IVPInspire Veterinary Partners Inc
$ 5.16
(42.15%)
3.68M
SQQQProShares UltraPro Short QQQ
$ 10.77
(0.28%)
2.87M
CTMXCytomX Therapeutics Inc
$ 3.10
(-26.01%)
2.55M

ARVN Discussion

View Posts
Monksdream Monksdream 3 months ago
ARVN new 52=week high
👍️0
Monksdream Monksdream 3 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 3 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 4 months ago
ARVN new 52 week high
👍️0
crudeoil24 crudeoil24 3 years ago
ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”
👍️0
biocqr biocqr 4 years ago
Advantages of PROTACs vs. inhibition...

message_id=152832655
👍️0
G-lupo G-lupo 4 years ago
Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25
👍️0
boo boo boo boo 4 years ago
Starting to see a chink in the armor!
👍️0
G-lupo G-lupo 4 years ago
Possibly wall at 30.50
👍️0
G-lupo G-lupo 4 years ago
I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price
👍️0
boo boo boo boo 4 years ago
The offering:

8-k
👍️0
boo boo boo boo 4 years ago
Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!
👍️0
boo boo boo boo 4 years ago
It doesn't have to be a PR:

#8
👍️0
G-lupo G-lupo 4 years ago
Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30
👍️0
boo boo boo boo 4 years ago
https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/
👍️0
G-lupo G-lupo 4 years ago
When did they Do a price target announcement? I didn’t see that.
👍️0
boo boo boo boo 4 years ago
If I were in this one (I'm not), I'd be finding the exit on the price target announcement.
👍️0
G-lupo G-lupo 5 years ago
Arvn looking good, defintely see $26-27
👍️0
G-lupo G-lupo 5 years ago
What you mean IBD?
👍️0
boo boo boo boo 5 years ago
Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...
👍️0
G-lupo G-lupo 5 years ago
I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul
👍️0
boo boo boo boo 5 years ago
Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.
👍️0
G-lupo G-lupo 5 years ago
What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60
👍️0
boo boo boo boo 5 years ago
Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!
👍️0
boo boo boo boo 5 years ago
Fook R's!

EOM
👍️0
boo boo boo boo 5 years ago
Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!
👍️0
PennyStock Alert PennyStock Alert 5 years ago
ARVN
👍️0
G-lupo G-lupo 5 years ago
This stock very volatile, no rhyme or reason why it’s been up and down.
👍️0
morokoy morokoy 5 years ago
Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/
👍️0

Your Recent History

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved